drug interaction of rosuvastatin diclo ceftriaxone and telmisartan
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
rosuvastatin diclofenac telmisartan ceftriaxone drug interactions clinical
Finding Sources
Finding Sources
Finding Sources
Searching the Web
diclofenac telmisartan interaction renal hyperkalemia NSAIDs ARB
Reading File
Searching the Web
rosuvastatin diclofenac interaction mechanism pharmacokinetic
Here is a thorough breakdown of the clinically relevant drug interactions among Rosuvastatin, Diclofenac, Ceftriaxone, and Telmisartan:
Drug Interactions: Rosuvastatin + Diclofenac + Ceftriaxone + Telmisartan
Overview of the Four Drugs
| Drug | Class | Primary Use |
|---|---|---|
| Rosuvastatin | HMG-CoA reductase inhibitor (statin) | Dyslipidemia |
| Diclofenac | NSAID (COX-1/COX-2 inhibitor) | Pain/inflammation |
| Ceftriaxone | 3rd-generation cephalosporin | Bacterial infections |
| Telmisartan | Angiotensin II receptor blocker (ARB) | Hypertension, CVD protection |
1. Diclofenac + Telmisartan (MAJOR - Clinically Significant)
Mechanism: Pharmacodynamic antagonism + nephrotoxic synergy
- NSAIDs like diclofenac inhibit prostaglandin synthesis in the kidney, reducing renal blood flow and GFR. ARBs like telmisartan block angiotensin II-mediated efferent arteriolar vasoconstriction - another key compensatory mechanism for maintaining glomerular filtration pressure.
- When both are combined, the kidney loses two major compensatory mechanisms simultaneously, substantially increasing the risk of acute kidney injury (AKI).
- This combination also blunts the antihypertensive effect of telmisartan (NSAIDs cause sodium/water retention, opposing ARB-mediated vasodilation).
- Hyperkalemia risk increases: telmisartan reduces aldosterone (reducing K+ excretion), and diclofenac reduces renal prostaglandins (also reducing K+ excretion via direct tubular effects).
Clinical significance: This is the most critical interaction in this combination. The risk escalates further if a diuretic is also present ("Triple Whammy" - NSAID + ARB/ACEI + diuretic = highest AKI risk, NNH ~158 over 1 year). A large case-control study confirmed a 31% increased rate of AKI with this triple combination vs. dual therapy alone.
Management: Avoid co-prescribing if possible. If unavoidable, use the lowest NSAID dose for the shortest duration, monitor serum creatinine and potassium within 1-2 weeks, and ensure adequate hydration.
2. Rosuvastatin + Diclofenac (MODERATE - Pharmacokinetic)
Mechanism: Transporter competition (BCRP/ABCG2)
- Rosuvastatin is a substrate of OATP1B1 (hepatic uptake) and BCRP (ABCG2) (efflux transporter). Its clearance is NOT primarily CYP3A4-dependent, which differentiates it from simvastatin/atorvastatin.
- Diclofenac also interacts with ABCG2 (BCRP) and ABCC2 (MRP2) transporters for its own absorption and excretion.
- Potential for modest increases in rosuvastatin plasma concentrations if transporter competition occurs.
- Diclofenac is primarily metabolized by CYP2C9; rosuvastatin is minimally metabolized by CYP2C9 (N-desmethyl rosuvastatin ~10% of dose), so CYP2C9 competition is generally not clinically significant at standard doses.
- Both drugs are independently hepatotoxic at high doses; concurrent use warrants liver enzyme monitoring.
Clinical significance: Generally minor at standard doses but watch for myopathy signs and liver enzyme elevation in patients on long-term combined therapy.
3. Rosuvastatin + Ceftriaxone (LOW - Indirect Risk)
Mechanism: Hepatotoxic additivity
- Ceftriaxone can cause cholestatic hepatotoxicity, particularly at high doses or prolonged use. It also forms insoluble calcium-ceftriaxone complexes causing biliary pseudolithiasis.
- Rosuvastatin carries a low but real risk of transaminase elevation.
- No direct pharmacokinetic interaction is documented (ceftriaxone is not CYP-metabolized; it does not inhibit OATP1B1 or BCRP to a clinically relevant extent).
- A case report published in PMC documented hepatotoxicity in a patient on IV ceftriaxone + statin (atorvastatin in that case), attributing it to combined hepatic stress.
Clinical significance: Low direct interaction risk. Monitor LFTs if both are given concurrently, especially in patients with pre-existing hepatic disease or at high ceftriaxone doses (>2 g/day).
4. Telmisartan + Rosuvastatin (MINOR)
Mechanism: Pharmacokinetic - OATP1B1 and CYP2C9
- Telmisartan undergoes glucuronidation (UGT1A3), not CYP metabolism, so there is no significant CYP-based interaction with rosuvastatin.
- Some data suggest telmisartan may modestly inhibit OATP1B1 hepatic uptake transporters, which could slightly increase rosuvastatin exposure, but this is not considered clinically significant at standard doses.
Clinical significance: Generally safe combination; no dose adjustment required. This combination (statin + ARB) is commonly and intentionally co-prescribed in cardiovascular risk patients.
5. Telmisartan + Ceftriaxone (MINIMAL)
- No direct pharmacokinetic interaction. Both are eliminated differently (telmisartan via biliary/fecal; ceftriaxone via biliary and renal).
- Ceftriaxone-induced diarrhea or volume depletion could theoretically potentiate hypotension in patients on telmisartan, but this is an indirect effect rather than a true drug-drug interaction.
Summary Table
| Drug Pair | Severity | Mechanism | Clinical Risk | Action |
|---|---|---|---|---|
| Diclofenac + Telmisartan | MAJOR | PD antagonism; renal prostaglandin + angiotensin blockade | AKI, hyperkalemia, reduced antihypertensive effect | Avoid; if used, monitor Cr + K+, use short course |
| Rosuvastatin + Diclofenac | Moderate | BCRP transporter competition; mild CYP2C9 overlap | Elevated rosuvastatin levels, hepatotoxic additivity | Monitor LFTs, watch for myalgia |
| Rosuvastatin + Ceftriaxone | Low | Additive hepatic stress (no PK interaction) | Transaminase elevation | Monitor LFTs in high-risk patients |
| Telmisartan + Rosuvastatin | Minor | Possible OATP1B1 modulation (minor) | Minimal at standard doses | No routine adjustment needed |
| Telmisartan + Ceftriaxone | Minimal | Volume depletion (indirect) | Hypotension if diarrhea/dehydration | Ensure hydration |
| Diclofenac + Ceftriaxone | Additive nephrotoxic | Both can impair renal function | AKI risk in volume-depleted patients | Monitor renal function |
Key Clinical Takeaways
- The most dangerous pair is Diclofenac + Telmisartan - this represents a well-documented major interaction causing AKI, hyperkalemia, and reduced BP control. Use with extreme caution.
- Rosuvastatin is relatively safer than other statins for drug interactions because it is NOT extensively metabolized by CYP3A4 - Goodman & Gilman notes pravastatin, fluvastatin, and rosuvastatin are less likely to cause myopathy with CYP3A4-interacting drugs compared to simvastatin.
- If a diuretic is also present alongside diclofenac + telmisartan, this creates the "Triple Whammy" - a well-known nephrotoxic triad requiring avoidance or very close monitoring.
- Asian patients on rosuvastatin have approximately 2-fold higher exposure due to pharmacogenomic differences in OATP1B1 - keep this in mind when adding potentially interacting drugs.
- Monitor: Serum creatinine, potassium, LFTs, and creatine kinase (CK) if myalgia develops.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14e; FDA Crestor Prescribing Information (2024); PMC Triple Whammy review; Drug-drug-gene interactions case report
This is a shared conversation. Sign in to Orris to start your own chat.